Observational studyCritical care (London, England)2026
Costs and complications of extracorporeal membrane oxygenation therapy in Australia and New Zealand.
Observational study in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03793257 (The EXCEL Registry), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The EXCEL Registry: A Comprehensive Binational Registry on the Treatment and Outcomes of Patients Requiring ECMO
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundExtracorporeal membrane oxygenation (ECMO) is a life-saving form of cardiopulmonary support for patients with severe refractory cardiopulmonary disease. It is a resource-intensive intervention requiring specialised equipment and personnel, with significant associated costs. This study aimed to determine the costs of care for patients who received ECMO in Australia and New Zealand, and to determine the impact of ECMO-related complications on costs.
methodsA prospective observational clinical registry analysis was performed using data from 1,345 patients commenced on ECMO in Australia and New Zealand between 2019 and 2022. Per patient resource use was costed based on data from hospital admission to hospital discharge. Key outcomes were mean total patient cost and costs associated with complications. Costs were reported in 2022 Australian Dollars.
resultsMean costs and daily ECMO costs varied significantly between ECMO modes. While total costs for venovenous (VV) ECMO was significantly more expensive (mean $287,264, standard deviation [SD] $251,193) than venoarterial (VA) ECMO (mean $215,128, SD $162,418) and extracorporeal cardiopulmonary resuscitation (ECPR) (mean $121,274, SD $131,893), daily costs while receiving ECMO were least costly for VV ECMO. Complications occurred in 57% of patients. Cost incrementally increased with number of complications. Mean costs were significantly higher in patients with infection (mean $292,197, SD $217,806) compared to those without (mean $161,674, SD $165,175). Key cost drivers were intensive care and hospital length of stay, and ECMO-related procedure costs.
conclusionsECMO costs were high, with venovenous ECMO being most expensive due to an increased length of stay. Total patient cost increased with additional ECMO complications. Accurate ECMO costs and complications data can enable informed health budgeting and identification of areas for clinical improvement. (Trial registration: NCT03793257).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.